Verismo Therapeutics raises funding and expands partnership with Penn Medicine
Penn spinout company Verismo Therapeutics has successfully raised $7 million in a pre-Series A round led by BRV Capital Management.
6 Million NIH Grant Funds New Penn Medicine Research on Cardiac Cell Development
The Penn research team, led by principal investigator Dr. Rajan Jain aims to study how cardiac cells establish and maintain their identity over a lifetime.
New Approaches to CAR-T Therapy
The FDA first approved of chimeric antigen receptor (CAR) T cell therapy in 2017, and Penn Medicine has since been dedicated to finding further applications to the treatment.
Future mRNA Vaccine Applications Highlighted
The New York Post recently published an article discussing future applications of mRNA, including vaccinations against tuberculosis, malaria, high cholesterol, HIV, and more.
4D Molecular Therapeutics (4DMT) Acquires Rights to Penn Medicine Invented Technology from Aevitas Therapeutics
Penn spinout Aevitas Therapeutics recently executed an asset purchase agreement with California-based biotechnology company 4D Molecular Therapeutics (4DMT).
Adult Schizophrenia Drug Wins FDA Approval
Teva Pharmaceuticals and MedinCell recently received approval from the U.S. Food and Drug Administration (FDA) for UZEDY™ (risperidone).
Penn Medicine Magazine Showcases Penn’s Drug Research and Development and Commercial Partnerships
The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging co
Bruce Levine Speaks on the Future of CAR-T Therapies
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
Fake
This technology is an intracerebral drug delivery system that consists of three flexible, retractable microcannulas housed within a single central catheter.